These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21613849)

  • 1. Pharmacologic renoprotection: are the stars finally moving into alignment?
    Stafford-Smith M
    Crit Care Med; 2011 Apr; 39(4):906-7. PubMed ID: 21613849
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of post-cardiopulmonary bypass acute kidney injury by endothelin A receptor blockade.
    Patel NN; Toth T; Jones C; Lin H; Ray P; George SJ; Welsh G; Satchell SC; Sleeman P; Angelini GD; Murphy GJ
    Crit Care Med; 2011 Apr; 39(4):793-802. PubMed ID: 21220998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
    Dhaun N; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2011 Aug; 58(2):e11-2. PubMed ID: 21709210
    [No Abstract]   [Full Text] [Related]  

  • 4. Relief of chronic neuropathic pain through endothelin antagonism.
    Murphy DM; O'Callaghan DS; Gaine SP
    Am J Med; 2010 Mar; 123(3):e7. PubMed ID: 20193818
    [No Abstract]   [Full Text] [Related]  

  • 5. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Updated treatment of primary pulmonary hypertension -- the role of endothelin receptor antagonists].
    Callejas Rubio JL; Ortego Centeno N; Navarro Pelayo F; Vallejo Rodríguez I
    Farm Hosp; 2004; 28(4):294-5. PubMed ID: 15369441
    [No Abstract]   [Full Text] [Related]  

  • 7. Endothelin receptor antagonists and scleroderma related digital ulcers.
    Lee WY; Faruqi S; Morice AH
    Acta Reumatol Port; 2013; 38(1):58-9. PubMed ID: 24131915
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease.
    Dhaun N; MacIntyre IM; Kerr D; Melville V; Johnston NR; Haughie S; Goddard J; Webb DJ
    Hypertension; 2011 Apr; 57(4):772-9. PubMed ID: 21357275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
    Wilkins MR
    Am J Respir Crit Care Med; 2004 Feb; 169(4):433-4. PubMed ID: 14766656
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective and mixed endothelin receptor antagonism in cardiovascular disease.
    Dhaun N; Pollock DM; Goddard J; Webb DJ
    Trends Pharmacol Sci; 2007 Nov; 28(11):573-9. PubMed ID: 17950470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
    Ghofrani HA
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S177-8. PubMed ID: 19718611
    [No Abstract]   [Full Text] [Related]  

  • 12. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitaxsentan (ICOS-Texas Biotechnology).
    Wu-Wong JR
    Curr Opin Investig Drugs; 2001 Apr; 2(4):531-6. PubMed ID: 11566012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
    Humbert M; Simonneau G
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Langleben D
    Clin Chest Med; 2007 Mar; 28(1):117-25, viii. PubMed ID: 17338931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.
    Hoeper MM; Olsson KM; Schneider A; Golpon H
    Eur Respir J; 2009 Jun; 33(6):1518-9. PubMed ID: 19483056
    [No Abstract]   [Full Text] [Related]  

  • 18. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
    Girgis RE; Frost AE; Hill NS; Horn EM; Langleben D; McLaughlin VV; Oudiz RJ; Robbins IM; Seibold JR; Shapiro S; Tapson VF; Barst RJ
    Ann Rheum Dis; 2007 Nov; 66(11):1467-72. PubMed ID: 17472992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
    Tilton RG; Munsch CL; Sherwood SJ; Chen SJ; Chen YF; Wu C; Block N; Dixon RA; Brock TA
    Pulm Pharmacol Ther; 2000; 13(2):87-97. PubMed ID: 10799286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.